Last $2.86 USD
Change Today -0.05 / -1.72%
Volume 76.0K
PSTI On Other Exchanges
As of 8:10 PM 09/30/14 All times are local (Market data is delayed by at least 15 minutes).

pluristem therapeutics inc (PSTI) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/21/14 - $4.63
52 Week Low
08/13/14 - $2.58
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

pluristem therapeutics inc (PSTI) Related Businessweek News

No Related Businessweek News Found

pluristem therapeutics inc (PSTI) Details

Pluristem Therapeutics Inc., through its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. The company focuses on the research, development, clinical trial, and manufacture of cell therapeutics products and related technologies for the treatment of various ischemic and inflammatory conditions. Its patented PLacental eXpanded (PLX) cells function as a platform that releases a number of therapeutic proteins in response to various local and systemic inflammatory and ischemic signals generated by the patient. The company’s PLX cells are grown using proprietary 3D micro-environment technology that produces an off-the-shelf allogeneic cell therapy products. It also develops PLX-PAD cells, which are in Phase-II clinical trial for use in the treatment of peripheral and cardiovascular, orthopedic, and pulmonary diseases, as well as for hematological and women’s health diseases; and PLX-RAD cells used for acute radiation syndrome treatment of animals, as well as products in pre-clinical trial for the treatment of pre-eclampsia and rotator-cuff repair. The company is also involved in the development and commercialization of a PLX cell-based product for the treatment of pulmonary arterial hypertension through its license agreement with the United Therapeutics Corporation; and commercialization agreement with CHA Bio&Diostech for conducting clinical trials and commercialization of PLX-PAD products in South Korea. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.

160 Employees
Last Reported Date: 09/11/14
Founded in 2001

pluristem therapeutics inc (PSTI) Top Compensated Officers

Executive Chairman and Chief Executive Office...
Total Annual Compensation: $503.7K
President and Chief Operating Officer
Total Annual Compensation: $270.0K
Chief Financial Officer, Vice President of Fi...
Total Annual Compensation: $129.9K
Compensation as of Fiscal Year 2014.

pluristem therapeutics inc (PSTI) Key Developments

Pluristem Therapeutics, Inc. Announces Strategic Opportunities to Co-Develop and Commercialize its PLacental eXpanded Cell Therapies in Japan

Pluristem Therapeutics Inc. announced that it is evaluating strategic opportunities to co-develop and commercialize its PLacental eXpanded cell therapies in Japan. Recent changes in Japan's laws governing regenerative medicine and the approval of stem cell therapies indicate the country may now offer the fastest track to commercialization in the world for regenerative medicine treatments. As part of the company’s strategy in Japan, on September 16, 2014, company executives presented to a group of Japanese pharmaceutical executives in Tokyo, and conducted a series of one-on-one meetings with Japanese companies exploring a potential partnership with Pluristem. To support its strategy in Japan, the company is working with The Sage Group and Sage's partner Waterfield HealthCom. Pluristem currently has co-development and out-licensing partnership agreements with United Therapeutics and CHA Bio&Diostech.

Israel's Ministry of Health Approves Pluristem's Commercial-Scale 3D Cell Manufacturing Process Used at its New Haifa Facility

Pluristem Therapeutics, Inc. announced that it has completed the approval process and received final clearance from a fifth regulatory agency for its 3D cell therapy manufacturing processes in use at its new facility in Haifa. The latest approval comes from Israel's Ministry of Health and follows similar clearances from the U.S. Food and Drug Administration, the European Union's Qualified Person, Germany's Paul Ehrlich Institute, and the South Korean Ministry of Food and Drug Safety. Pluristem's GMP manufacturing site is located in MATAM industrial park, in Haifa, Israel and is equipped with 500 square meters of clean rooms in which PLX cells can be manufactured in sufficient quantities to support late-phase clinical trials and commercial demand at time of regulatory approval. Pluristem manufactures its products in full compliance with the U.S. Food and Drug Administration (FDA) and European Medicines Agencies (EMA) current Good Manufacturing Practices (cGMP). Pluristem believes that control of the production process is critical for the successful manufacture of cell therapies and invests significantly in developing highly efficient, cutting-edge culturing systems for its range of PLX cell products.

Pluristem Therapeutics, Inc. Initiates South Korean Arm of Multinational Phase II Intermittent Claudication Trial

Pluristem Therapeutics Inc. announced the initiation of South Korean sites in the Phase II study assessing PLacental eXpanded (PLX) cells in the treatment of intermittent claudication (IC). Patient screening is now underway at three clinical centers, making South Korea the fourth country to participate in this randomized, double-blind, placebo-controlled Phase II trial. The trial has been ongoing at clinical sites in the U.S., Israel and Germany with an enrollment target of 150 patients. In May 2014, Pluristem received clearance from the South Korean Ministry of Food and Drug Safety (MFDS) to use PLX cells in South Korean trials.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PSTI:US $2.86 USD -0.05

PSTI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advanced Cell Technology Inc $7.41 USD -0.54
Antares Pharma Inc $1.83 USD -0.04
Athersys Inc $1.39 USD +0.02
Cardica Inc $1.07 USD 0.00
NeoStem Inc $5.53 USD -0.29
View Industry Companies

Industry Analysis


Industry Average

Valuation PSTI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 520.3x
Price/Book 3.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 389.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PLURISTEM THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at